Beclometasone for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  De Coster, Daan A ^a   Jones, Melvyn ^b   Thakrar, Nikita ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; PLACEBO; GLUCOCORTICOID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QTC INTERVAL; QUALITY OF LIFE; REVIEW; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; DRUG EFFECTS; META ANALYSIS; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG EFFECT;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BECLOMETHASONE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899469858     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009769.pub2     Document Type: Review

References (83)

1. Calverley PM, Kuna P, Monsó E, Costantini M, Petruzzelli S, Sergio F, et al.Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine 2010;104(12):1858-68. [DOI: 10.1016/j.rmed.2010.09.008;: http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712]
2. 1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine 1995;151:A463.
3. van Grunsven PM. Chapter 8: Beneficial clinical effects of a two-year treatment with inhaled beclomethasone dipropionate 1500 μg daily in moderate to severe chronic obstructive pulmonary disease - a multicenter randomized placebo-controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD) - Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002]
4. Weir DC, Bale GA, Bright P, Burge PS. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy 1999;29(Suppl. 2):125-8. [DOI: 10.1046/j.1365-2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835]
5. Boothman-Burrell D, Delany SG, Flannery EM, Hancox RJ, Taylor DR. The efficacy of inhaled corticosteroids in the management of non asthmatic chronic airflow obstruction. New Zealand Medical Journal October 1997;110(1053):370-3. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/9364183]
6. Dinc M, Tchugunova Y, Dinc S, Cinarli B, Atasever T, Oz M. Decreased osteocalcin levels in patients with chronic obstructive pulmonary disease using long-term inhaled beclomethasone dipropionate. Metabolism: Clinical and Experimental 2001;50(11):1336-9. [DOI: 10.1053/meta.2001.27231;: http://www.sciencedirect.com/science/article/pii/S0026049501997914; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/11699053]
7. John M, Bosse S, Oltmanns U, Schumacher A, Witt C. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2005;99(11):1418-24. [DOI: 10.1016/j.rmed.2005.03.034; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/15894479]
8. John M, Bosse S, Schumacher A, Oltmanns U, Witt C. Effect of inhaled beclomethasone HFA 134 (QVAR/Ventolair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego. [A43] [Poster: F43].
9. Miravitlles M, Alvarez Sala JL, Lamarca R, Ferrer M, Masa F, Verea H. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Quality of Life Research 2002;11(4):329-38.
10. Ouyang R, Yin B. Clinical study of inhaled corticosteroid in non-asthmatic chronic obstructive pulmonary disease. Chung-Hua Chieh Ho Ho Hu Hsi Tsa Chih 1998;21(8):497-9. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/11360524]
11. Shmelev EI, Kunicina YL. Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease. Clinical Drug Investigation 2006;26(3):151-9. [: http://adisonline.com/druginvestigation/Abstract/2006/26030/Comparison_of_Fenspiride_with_Beclomethasone_as.5.aspx]
12. Struijs A, Mulder H. The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide. Netherlands Journal of Medicine 1997;50(6):233-7. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/9232087]
13. Thompson AB, Mueller MB, Heires AJ, Bohling TL, Daughton D, Yancey SW, et al.Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. American Review of Respiratory Disease 1992;146(2):389-95. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/1489129]
14. Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini EM, et al.Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:503-9. [DOI: 10.2147/COPD.S23746;: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206766/]
15. Tzani P, Crisafulli E, Nicolini G, Clini E, Aiello M, Chetta A, et al.Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD [Abstract]. European Respiratory Society 20th Annual Congress; 2010 September 18-22; Barcelona.
16. van Schayck CP, Dompeling E, Rutten MP, Folgering H, van den Boom G, van Weel C. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995;107(5):1199-205. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/7750306]
17. Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990;45(2):112-17. [: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC462320/; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/2180105]
18. Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate 750 μg and 1500 μg twice daily and 40 mg oral prednisolone on lung function, symptoms and bronchial hyperresponsiveness in patients with non-asthmatic airflow obstruction. Thorax 1993;48(4):309-16. [: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464423/; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/8511727]
19. Vengerov B. Effectiveness of long-term treatment with inhaled corticosteroids in metal workers with COPD. European Respiratory Journal Supplement 1998;12(Suppl 28):413S.
20. Singh D, Kampschulte J, Wedzicha JA, Jones PW, Cohuet G, Corradi M, et al. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. European Respiratory Journal 2013;41(1):12-7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766]
21. Wedzicha WA. BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013).
22. Adams N, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4]
23. Agarwal R, Agarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010;137(2):318-25.
24. Anon. Preventing exacerbations in COPD. Drug and Therapeutics Bulletin 2010;48(7):74-7.
25. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. American Review of Respiratory Disease 1987;136:225-43. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/3605835]
26. American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients With COPD. 1.2. New York: American Thoracic Society, 2004.
27. Bradley-Drummond M, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407-16.
28. Britton M. The burden of COPD in the U.K.: results from the confronting COPD survey. Respiratory Medicine 2003;97(Suppl C):S71-9.
29. Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, et al.Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technology Assessment 2001;5(26):1-149. [: http://www.ncbi.nlm.nih.gov/pubmed/11701099; PUBMED: 11701099]
30. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. British Medical Journal 2001;323(7318):896-900.
31. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. British Medical Journal 1972;1(5800):585-90.
32. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):S1-8. [: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1765890/; PMCID: PMC1765890]
33. Buscemi N, Hartling L, Vandermeer B, Tjosvold L, Klassen TP. Single data extraction generated more errors than double data extraction in systematic reviews. Journal of Clinical Epidemiology 2006;59:697-703.
34. Cochrane Airways Group. Developing a search strategy for an Airways Group systematic review. http://airways.cochrane.org/authors (accessed 2 January 2012).
35. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al.American Thoracic Society, European Respiratory Society Task Force on Outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal 2008;31(2):416-69. [DOI: 10.1183/09031936.00099306; PUBMED: 18238951]
36. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al.The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New England Journal of Medicine 2004;350(10):1005-12. [PUBMED: www.ncbi.nlm.nih.gov/pubmed/14999112]
37. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997;52(1):55-8.
38. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al.American College of Chest Physicians, American College of Asthma, Allergy, Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127(1):335-71. [DOI: 10.1378/chest.127.1.335;: http://www.ncbi.nlm.nih.gov/pubmed/15654001; PUBMED: 15654001]
39. Fabbri L, Burge PS, Croonenborgh L, Warlies F, Weeke B, Ciaccia A, et al.Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48(8):817-23.
40. Fletcher CM, Jones NL, Burrows B, Niden AH. American emphysema and British bronchitis: a standardized comparative study. American Review of Respiratory Disease 1964;90:1-13.
41. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Annals of Family Medicine 2006;4(3):253-62.
42. Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc., (accessed 12 January 2011).
43. Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.org/ (accessed 7 October 2013).
44. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
45. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
46. Ivancsó I, Böcskei R, Müller V, Tamási L. Extrafine inhaled corticosteroid therapy in the control of asthma. Journal of Asthma and Allergy 2013;6:69-80. [DOI: 10.2147/JAA.S25415;: http://www.ncbi.nlm.nih.gov/pubmed/23776339; PUBMED: 23776339]
47. Izquierdo JL. Chronic obstructive lung disease: corticosteroids [Corticoides en la EPOC]. Archivos de Bronconeumologia 2003;39(Suppl 3):25-7.
48. Jones A, Fay JK, Burr MI, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003537]
49. Kelly HW. Comparison of inhaled corticosteroids: an update. The Annals of Pharmacotherapy 2009;43(3):519-27.
50. Kemp L, Haughney J, Barnes N, Sims E, von Ziegenweidt J, Hillyer EV, et al.Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: a real world observational study. ClinicoEconomics and Outcomes Research 2010;2:75-85. [: http://www.ncbi.nlm.nih.gov/pubmed/21935316/; PUBMED: 21935316]
51. Kunka R, Andrews S, Pimazzoni M, Callejas S, Ziviani L, Squassante L, et al.From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respiratory Medicine 2000;94(Suppl B):S10-6. [PUBMED: 10919680 ]
52. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. European Respiratory Journal 1998;12:1346-53. [DOI: 10.1183/09031936.98.12061346; PUBMED: 9877489]
53. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Archives of Internal Medicine 1999;159(9):941-55.
54. Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. European Respiratory Journal 2010;35(5):1003-21.
55. Longest PW, Tian G, Walenga RL, Hindle M. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharmaceutical Research 2012;29(6):1670-88. [DOI: 10.1007/s11095-012-0691-y;: http://www.ncbi.nlm.nih.gov/pubmed/22290350; PUBMED: 22290350]
56. Lucas AEM, Smeenk FWJM, Smeele IJ, Van Schayck CP. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients: an exploratory study. Family Practice 2008;25(2):86-91.
57. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580-6.
58. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al.Systemic effect comparisons of six inhaled corticosteroid preparations. American Journal of Respiratory Care Medicine 2002;165(10):1377-83.
59. ® 50 micrograms peractuation pressurised inhalation solution (beclometasone dipropionate) PL 08829/0133 Public Assessment Report. www.mhra.gov.uk/home/groups/l-unit1/documents/./con014210.pdf (accessed 26 June 2013).
60. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.Standardisation of spirometry. European Respiratory Journal 2005;26(2):319-38.
61. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
62. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3]
63. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006829.pub2/abstract]
64. National Collaborating Centre for Acute and Chronic Conditions. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. http://www.nice.org.uk/guidance/CG101 (accessed 7/10/13).
65. National Prescribing Centre. COPD: data focused commentary. http://www.npc.nhs.uk/therapeutics/respiratory/copd/data.php (accessed 1 February 2012).
66. Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM, Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. European Respiratory Journal 2007;29(4):682-9. [DOI: 10.1183/09031936.00095906;: http://www.ncbi.nlm.nih.gov/pubmed/17107988; PUBMED: 17107988]
67. Price D, Haughney J, Sims E, Ali M, von Ziegenweidt J, Hillyer EV, et al.Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. Journal of Asthma and Allergy 2011;4:37-47. [DOI: 10.2147/JAA.S17709;: http://www.ncbi.nlm.nih.gov/pubmed/21698214; PUBMED: 21698214]
68. Quanjer PH. Standardized lung function testing. Bulletin Europeen de Physiopathologie Respiratoire 1983;19(Suppl 5):7-10.
69. Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, et al.Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003902]
70. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
71. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morri H, et al.Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis International 2003;14(3):179-90.
72. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136(4):1029-38.
73. Selroos O, Borgstrom L, Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Therapeutic Advances in Respiratory Disease 2009;3(2):81-91.
74. Sin DA, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A, et al.Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:7129.
75. Spencer S, Evans DJ, Karner C, Cates CJ. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD007033.pub3]
76. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. European Respiratory Journal 2009;34(1):13-6.
77. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356(8):775-89.
78. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al.Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54(1):7-14. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10343624]
79. Wales D, Makker H, Kane J, McDowell P, O'Driscoll BR. Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest 1999;115(5):1278-84.
80. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2]
81. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: WHO Press, 2008.
82. Yang IA, Fong K, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD002991.pub2]
83. Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002991.pub3/abstract]